Odyssey Capital Advisors Inc. Acquires New Position in Stryker Corporation $SYK

Odyssey Capital Advisors Inc. acquired a new stake in Stryker Corporation (NYSE:SYK) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,867 shares of the medical technology company’s stock, valued at approximately $656,000.

A number of other hedge funds have also recently added to or reduced their stakes in SYK. Brighton Jones LLC lifted its position in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new stake in Stryker in the second quarter valued at about $205,000. Marshall Wace LLP lifted its position in Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after purchasing an additional 77,831 shares during the period. Nebula Research & Development LLC acquired a new stake in Stryker in the second quarter valued at about $219,000. Finally, HUB Investment Partners LLC acquired a new stake in Stryker in the second quarter valued at about $253,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

SYK stock opened at $306.74 on Monday. The firm has a 50 day moving average of $329.68 and a 200-day moving average of $351.50. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company has a market cap of $117.59 billion, a price-to-earnings ratio of 35.50, a PEG ratio of 1.93 and a beta of 0.80.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the previous year, the business posted $2.84 earnings per share. Stryker’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Activity

In other news, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the sale, the vice president directly owned 177 shares in the company, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Truist Financial restated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Jefferies Financial Group restated a “buy” rating and issued a $465.00 price objective on shares of Stryker in a research report on Wednesday, March 4th. UBS Group reduced their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. Piper Sandler restated an “overweight” rating on shares of Stryker in a research report on Tuesday, January 27th. Finally, Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.